Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
Status:
Recruiting
Trial end date:
2032-07-31
Target enrollment:
Participant gender:
Summary
Currently, daratumumab, lenalidomide, and dexamethasone are given continuously (non-stop).
Some recent observations suggest that stopping daratumumab after about a year and a half of
treatment may work just as well as giving it continuously with lenalidomide and
dexamethasone. This study is being done to answer the question: is less daratumumab treatment
as good as more?
Phase:
Phase 3
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborators:
Canadian Institutes of Health Research (CIHR) Myeloma Canada